Viatris (VTRS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Bill Szablewski - Head of Capital MarketScott Smith - Director & CEOPhilippe Martin - Chief R&D OfficerDoretta Mistras - CFOChris Schott - Managing DirectorCorinne Le Goff - Chief Commercial OfficerAshwani Verma - Executive Director - SMID Biotech & BiopharmaUmer Raffat - Senior Managing Director Conference Call Participants David Amsellem - Sr. Research AnalystPavan Patel - Analyst Operator Please also note today's event is ...

Viatris (VTRS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Bill Cyblowski, Head of Capital Markets. Please go ahead. Speaker1 Good morning, everyone. Welcome to our Q1 twenty twenty five earnings call. With us today is our CEO, Scott Smith CFO, Doretta Mistras Chief R and D Officer, Philippe Martin and Chief Commercial Officer, Karine Lagasse. During today's call, we will be making forward looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Viatris (VTRS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.04%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.57 per share when it actually produced earnings of $0.54, delivering a surprise of -5.26%.Over the last four quarters, the company ...

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook PITTSBURGH – May 8, 2025 – Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive Commentary "2025 is off to a good start as we continue to focus on executing our strategic priorities," said Scott A. Smith, CEO, Viatris. "Our growing pipeline, capital discipline, operational execution, and significant global scope give us confidence in our ability to navigate the perio ...

Q1 2025 Earnings May 8, 2025 1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of ...

Core Insights - Viatris Inc. reported first quarter 2025 financial results, reaffirming its 2025 outlook, with total revenues of $3.25 billion, down 11% year-over-year, primarily due to the negative Indore Impact [1][6][12] - The company experienced a significant non-cash goodwill impairment charge of $2.9 billion, leading to a U.S. GAAP net loss of $3.04 billion for the quarter [12][27][38] - Viatris continues to focus on capital allocation, returning over $450 million to shareholders year-to-date, including over $300 million in share repurchases [4][14] Financial Performance - Total revenues for Q1 2025 were $3,254.3 million, down from $3,663.4 million in Q1 2024, reflecting an 11% decrease [6][38] - Total net sales decreased to $3,243.2 million from $3,653.5 million, also an 11% decline [6][38] - Gross profit was reported at $1,161.2 million, down 23% from $1,504.0 million in the previous year [8][38] - Adjusted EBITDA for the quarter was $923 million, a decrease of 23% compared to $1,193.4 million in Q1 2024 [8][12] Market Segments - Developed markets saw a revenue decline of 13%, while emerging markets experienced a 17% drop [6] - Greater China reported a 2% increase in revenues, indicating some resilience in that market [6] - Brands net sales decreased by 8%, while generics saw a 16% decline, reflecting the expected negative Indore Impact [6][12] Pipeline and Product Development - The company achieved positive results from three Phase 3 studies, including EFFEXOR® for anxiety disorder and a novel formulation of meloxicam for acute pain [12][35] - Viatris plans to submit a New Drug Application (NDA) for the new meloxicam formulation by the end of 2025 [35] - The company expects to generate approximately $450 million to $550 million in new product revenues in 2025 [12][35] Capital Allocation Strategy - Viatris reaffirmed its commitment to returning capital to shareholders, with expectations of $500 million to $650 million in total share repurchases for 2025 [14][16] - Year-to-date, the company has returned over $450 million to shareholders, including dividends and share repurchases [4][14] Financial Guidance - The company estimates U.S. GAAP net cash provided by operating activities for 2025 to be between $2.2 billion and $2.5 billion, with a midpoint of approximately $2.35 billion [16][26] - Financial guidance for 2025 remains unchanged, excluding the impact of divestiture-related taxes and transaction costs [16][18]

Treatment With XULANE LO Low Estrogen Dose Achieved Primary and All Secondary Efficacy and Safety EndpointsResults Demonstrated Potential Best-In-Class Patch Performance New Drug Application Submission to U.S. FDA Anticipated in the Second Half of 2025PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly ...

Core Insights - Viatris Inc. announced positive results from its Phase 3 trials for MR-107A-02, a fast-acting formulation of meloxicam, demonstrating significant pain relief compared to placebo and reduced opioid usage [1][2][3] - The company plans to submit a New Drug Application to the U.S. FDA by the end of 2025 based on these results [1][5] Group 1: Study Results - Both Phase 3 trials met primary endpoints, showing statistically significant and clinically meaningful improvement in pain management [2][4] - In the herniorrhaphy trial, the least squares mean difference in pain intensity (SPID0-48h) between MR-107A-02 and placebo was 50.1 (95% CI: 35.4, 64.8; p<0.001), while in the bunionectomy trial, it was 82.7 (95% CI: 62.0, 103.4; p<0.001) [4] - MR-107A-02 resulted in a higher percentage of opioid-free patients: 72.6% in herniorrhaphy versus 58.6% in placebo (p=0.002) and 56.9% in bunionectomy versus 33.1% in placebo (p<0.001) [4] Group 2: Efficacy and Safety - The treatment was well tolerated, with adverse events comparable to placebo, and no deaths reported [4] - The drug showed superior pain control compared to the opioid comparator (tramadol) in both surgical models, with faster onset of pain relief [4][3] Group 3: Future Plans - Viatris aims to present full results from the Phase 3 studies at upcoming conferences, including PAINWeek 2025 [5] - The company is building on previous Phase 2 data from dental pain studies to support its application for MR-107A-02 [5][10]

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. ...